Rate of relapse and reactions in MB leprosy patients after 24 and 12 months of MDT in Maharashtra [1]

Indian Journal of Leprosy

Volumn 76, Issue 3, 2004, Pages 229-230

  Deshpande, J ^a   Chougule, S G ^a   Thakar, U H ^b   Revankar, C R ^b  

^a Health Services   (India)

^b RRE Society   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE;

ANTIINFLAMMATORY ACTIVITY; DISEASE TRANSMISSION; DRUG RESPONSE; FOLLOW UP; HEALTH PROGRAM; HUMAN; INCIDENCE; INDIA; INFORMATION PROCESSING; LEPROSY CONTROL; LETTER; MULTIBACILLARY LEPROSY; NERVE INJURY; RELAPSE; TREATMENT PLANNING;

DRUG THERAPY, COMBINATION; HUMANS; INCIDENCE; INDIA; LEPROSTATIC AGENTS; LEPROSY; RECURRENCE;

EID: 4444306090     PISSN: 02549395     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Ganapati R, Bulchand HO, Pai VV et al (2001). Int J Lepr Other Mycobact Dis 69: 114-5
2. Report of a workshop on "Experiences with ROM treatment for SSL-PB leprosy and 12-month MDT for MB leprosy". Bulletin of the Leprosy Elimination Alliance 1(4): 15-16
3. Sudhakar KS, Bhusakade RA, Desikan KV (2003). A review of reaction cases of leprosy in a field unit. Paper presented at the IAL National Workshop on "Reactions in Leprosy". Jamnagar, Gujarat, January 2003.
4. WHO (1998). WHO Expert Committee on Leprosy. Seventh report. WHO Technical Report Series No. 874. Geneva: World Health Organization